Muraglitazar

CAS: 331741-94-7

Ref. 3D-FM26101

Informação sobre produto

• Nome: Muraglitazar
• Sinónimos: N-[(4-Methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine, Bms-298585, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, N-(4-Methoxyphenoxycarbonyl)-N-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzyl]glycine, N-[(4-methoxyphenoxy)carbonyl]-N-{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]benzyl}glycine, Pargluva

Descrição

Muraglitazar is a low potency polymerase chain inhibitor. Muraglitazar has been shown to inhibit the transcription-elongation process of RNA synthesis in humans and other mammals by binding to the enzyme, which prevents the formation of an active site that is required for DNA synthesis. Muraglitazar has also been shown to have therapeutic effects on infectious diseases such as HIV and malaria. It has also shown some promise in treating cancer, although it does not have any anti-tumor activity. Muraglitazar has been shown to be toxic in animal studies and may induce carcinogenic potential in humans. Muraglitazar is metabolized through a number of metabolic transformations, including hydrolysis by esterases or glucuronidases, oxidation by cytochrome P450 enzymes, reduction by glutathione reductase, or conjugation with glucuronic acid. This drug has been shown to have beneficial effects on congestive heart failure and diabetic neuropathy in vivo models

• Marca: Biosynth

Propriedades químicas

• Peso molecular: 516.54 g/mol
• Fórmula: C₂₉H₂₈N₂O₇
• Pureza: Min. 95%
• Cor/forma: Powder
• InChI: InChI=1S/C29H28N2O7/c1-20-26(30-28(37-20)22-6-4-3-5-7-22)16-17-36-24-10-8-21(9-11-24)18-31(19-27(32)33)29(34)38-25-14-12-23(35-2)13-15-25/h3-15H,16-19H2,1-2H3,(H,32,33)
• Chave InChI: InChIKey=IRLWJILLXJGJTD-UHFFFAOYSA-N
• SMILES: COc1ccc(OC(=O)N(CC(=O)O)Cc2ccc(OCCc3nc(-c4ccccc4)oc3C)cc2)cc1